<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Oncohematology</journal-id><journal-title-group><journal-title xml:lang="en">Oncohematology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкогематология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8346</issn><issn publication-format="electronic">2413-4023</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">500</article-id><article-id pub-id-type="doi">10.17650/1818-8346-2021-16-4-12-22</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>SUPPORTIVE THERAPY ASPECTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>АСПЕКТЫ ПОДДЕРЖИВАЮЩЕЙ ТЕРАПИИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Results and prospects for the development of supportive therapy in Russia. Based on the materials of the first Best of MASCC conference in Russia</article-title><trans-title-group xml:lang="ru"><trans-title>Итоги и перспективы развития поддерживающей терапии в России. По материалам первой в России конференции Best of MASCC</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Snegovoy</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Снеговой</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1"><institution></institution></aff><pub-date date-type="pub" iso-8601-date="2021-11-11" publication-format="electronic"><day>11</day><month>11</month><year>2021</year></pub-date><volume>16</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><history><date date-type="received" iso-8601-date="2021-11-10"><day>10</day><month>11</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-11-10"><day>10</day><month>11</month><year>2021</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncohematology.abvpress.ru/ongm/article/view/500">https://oncohematology.abvpress.ru/ongm/article/view/500</self-uri><abstract xml:lang="en"><p>.</p></abstract><trans-abstract xml:lang="ru"><p>9 октября 2020 г. впервые в России под эгидой общества специалистов поддерживающей терапии в онкологии (Russian Society of Supportive care in Oncology, RASSC) и Многонациональной ассоциации поддерживающей помощи при раке (The Multinational Association of Supportive Care in Cancer, MASCC) состоялась масштабная международная конференция, посвященная проблемам поддерживающей терапии в онкологии, Best of MASCC. около 500 слушателей из разных городов России, Украины, Казахстана, Латвии, Австралии, Израиля, Франции, Швейцарии, Нидерландов, США присоединились к онлайн-конференции. С видеоматериалами конференции можно ознакомиться на сайте RASSC (<ext-link ext-link-type="uri" xlink:href="http://www.rassc.org">www.rassc.org</ext-link>).</p></trans-abstract><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Video materials of the Best of MASCC RASSC symposium. Available at: https://rassc.org/ru/events/symposium. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Видеоматериалы симпозиума RASSC Best of MASCC. Доступно по: https://rassc.org/ru/events/symposium.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><mixed-citation>Balboni T.A., Hui K.K.P., Kamal A.H. Supportive Care In Lung Cancer: Improving Value In The Era Of Modern Therapies. Am Soc Clin Oncol Educ Book 2018:38:716–25. DOI: 10.1200/EDBK_201369.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Taberna M., Gil Moncayo F., Jané­Salas E. et al. The Multidisciplinary Team (MDT) approach and quality of care. Front Oncol 2020;10:85. DOI: 10.3389/fonc.2020.00085.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Principles of multidisciplinary care. Cancer Australia has developed web­based practical tools to assist health professionals and health service administrators implement MDC at the local level. Available at: https://www.canceraustralia.gov.au.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Costa L., Badia X., Chow E. et al. Impact of skeletal complications on patients’ quality of life, mobility, and functional independence. Support Care Cancer 2008;16(8):879–89. DOI: 10.1007/s00520­008­0418­0.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Kimura T. Multidisciplinary approach for bone metastasis: a review. Cancers (Basel) 2018;10(6):156. DOI: 10.3390/cancers10060156.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Marceca G.P., Londhe P., Calore F. Management of cancer cachexia: attempting to develop new pharmacological agents for new effective therapeutic options. Front Oncol 2020;10:298. DOI: 10.3389/fonc.2020.00298.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Jung J.H., Shin D.W., Kim J. et al. Primary granulocyte colony­stimulating factor prophylaxis in metastatic pancreatic cancer patients treated with FOLFIRINOX as the first­line treatment. Cancers (Basel) 2020;12(11):3137. DOI: 10.3390/cancers12113137.</mixed-citation></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Snegovoy A.V. Rational supportive therapy of drug anticancer treatment. Dis. … doctor of medical sciences. Moscow, 2016. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Снеговой А.В. Рациональная тактика поддерживающей терапии лекарственного противоопухолевого лечения. Автореф. дис. … д­ра мед. наук. М., 2016.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><mixed-citation>Vamvakas E.C., Blajchman M.A. Transfusion­related immunomodulation (TRIM): an update. Blood Rev 2007;21(6):327–48. DOI: 10.1016/j.blre.2007.07.003.</mixed-citation></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Hofmann A., Aapro M., Fedorova T.A. et al. Patient blood management in oncology in the Russian Federation. Resolution to improve oncology care. Sovremennaya onkologiya = Journal of Modern Oncology 2020;22(3):59–78. (In Russ.). DOI: 10.26442/18151434.2020.3.200340.</mixed-citation><mixed-citation xml:lang="ru">Хофманн А., Аапро М., Федорова Т.А. и др. Менеджмент крови пациентов в онкологии в Российской Федерации. Резолюция во имя улучшения оказания помощи онкологическим больным. Современная онкология 2020;22(3): 59–78.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Webinar “Preventive vaccination of cancer patients during immunotherapy. 10 questions from an oncologist to an infectious disease specialist”. Available at: https://rassc.org/ru/events/club. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Вебинар «Профилактическая вакцинация онкологических пациентов на фоне иммунотерапии. 10 вопросов онколога инфекционисту». Доступно по: https://rassc.org/ru/events/club.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
